--- slug: microdosing type: practice subsection: somatic-wellness created: 2026-06-09 updated: 2026-06-09 summary: "The sub-perceptual use of LSD, psilocybin, or another psychedelic on a schedule, usually for mood, focus, creativity, or wellbeing, with practitioner claims that run well ahead of placebo-controlled evidence." related: wellness-culture: relation: informed-by note: "Microdosing's productivity and self-optimization frame belongs to the wider wellness culture that turns inner state into something to tune." meditation: relation: complements note: "Many practitioners use microdosing alongside meditation, journaling, or contemplative practice rather than as a stand-alone intervention." ayahuasca: relation: contrasts-with note: "Ayahuasca is a full ceremonial psychedelic encounter; microdosing is the low-dose, usually self-directed attempt to stay below the threshold of a trip." breathwork: relation: contrasts-with note: "Breathwork is a non-drug route to altered or regulated states, while microdosing uses a small dose of a psychoactive substance." psychedelic-harms: relation: risks note: "Medication interactions, dosing uncertainty, psychiatric destabilization, contaminated products, and legal exposure belong in Psychedelic Harms rather than in this practice article." --- # Microdosing > **Practice** > > Something people do: ritual, method, exercise, ceremony, modality, or reading. *The practice of taking a sub-perceptual dose of a psychedelic, most often LSD or psilocybin, on a repeating schedule in order to seek mood, focus, creativity, or wellbeing without entering a full psychedelic session.* Microdosing is the psychedelic practice designed not to feel like a psychedelic practice. The dose is meant to sit below obvious intoxication: no visions, no ego dissolution, no ceremony, no day set aside for recovery. A person takes a small amount, goes to work, writes, meditates, parents, or exercises, and watches for a subtle shift in tone. That ordinary-life setting is the point. ## What the practice is Microdosing usually means taking about one-tenth to one-twentieth of a typical psychedelic dose, though the actual amount varies by substance, preparation, and person. The most common substances are LSD and psilocybin mushrooms. Some people use mescaline, DMT analogues, or other entheogens, but LSD and psilocybin dominate the public conversation because they are easier to discuss as repeated, low-dose protocols. Two protocols supply most of the practice's current shape. The **Fadiman protocol**, associated with psychologist James Fadiman, uses one dose day followed by two non-dose days: dose, observe the next day, reset the third day, then repeat. The spacing is meant to avoid tolerance and to make comparison possible. The practitioner journals mood, focus, sleep, creativity, and social behavior across the cycle. The **Stamets stack**, associated with mycologist Paul Stamets, uses psilocybin with lion's mane mushroom and niacin, usually on a more frequent on-off rhythm. Its claim is more specific: that the combination may support nerve growth or cognitive repair. That claim is widely repeated in wellness and biohacking circles, but the stack itself has not been validated as a protocol in placebo-controlled trials. ## What the practitioner does In most microdosing there is no facilitator. The practitioner is the person designing and monitoring her own experiment. She chooses a substance, chooses a schedule, prepares or obtains the dose, and decides what counts as too much, too little, or enough. The work is therefore half pharmacological and half observational. The better versions are boring on purpose. The practitioner measures the dose as carefully as the material allows, keeps the rest of the day ordinary, records what happened, and resists the urge to declare success after one pleasant morning. Many people track mood, sleep, concentration, exercise, meditation, and social ease, because any of those can explain a good or bad day. In coaching or underground guide settings, the practitioner's role shifts toward protocol design and interpretation. A coach may suggest the schedule, help set intentions, and review the journal. That can help, but it also blurs easily into authority without licensure, especially when the coach makes medical, trauma, or psychiatric claims. The harm side of that belongs in [Psychedelic Harms](psychedelic-harms.md). ## What the participant does The participant takes the dose and then lives the day. The aim is to remain functional enough that ordinary tasks are possible. If the person feels unmistakably high, sees visual effects, cannot drive, cannot work, or needs a ceremonial container, the dose is no longer micro in the practical sense. Reports often sound modest: more patience, a smoother mood, less rumination, easier creative flow, less resistance to chores, more interest in meditation or exercise. Others feel nothing, or feel irritable, wired, emotionally exposed, or subtly distracted. That spread is why the best self-experiments track non-dose days too. A person can mistake novelty, expectation, sleep, diet, or the simple decision to pay attention for the effect of the substance. The practice asks the participant to notice without dramatizing. That's harder than it sounds. Psychedelic culture gives the dose a strong story before anything happens, and the story itself can change the day. ## Setting, sequence, and materials Microdosing belongs to ordinary settings more than to ceremony. It happens at home, at a desk, before a walk, before meditation, or at the start of a planned workday. Some people pair it with journaling, breathwork, yoga, therapy homework, or time in nature. Others treat it as a productivity tool, closer to caffeine or nootropics than to ritual. The materials are the substance, a measured dose, a schedule, and a record. LSD microdosing often uses a tiny portion of a blotter or a volumetric dilution so the dose can be divided more evenly. Psilocybin microdosing usually uses dried mushrooms ground into capsules or weighed in small amounts. Measurement is one of the weak points: potency varies, home preparation is imprecise, and underground products are not standardized. A common sequence runs for several weeks: choose a baseline period, begin the protocol, record dose days and off days, pause after a cycle, and look back before changing anything. Serious practitioners often value the off days as much as the dose days because they show whether any perceived benefit lasts, rebounds, or disappears when expectation settles. The legal reality is plain. In most jurisdictions, LSD and psilocybin remain controlled substances outside narrow research, religious, or state-supervised exceptions. Decriminalization in a city or state does not make the practice federally legal in the United States. The article can describe microdosing as a real practice without pretending its legal status is settled. ## Claimed mechanism The biological claim starts with serotonin. Classic psychedelics such as LSD and psilocybin act mainly through the 5-HT2A receptor system, which is involved in perception, mood, cognition, and cortical flexibility. At full doses, that action can produce the altered states associated with psychedelic sessions. Microdosing claims that a much smaller dose can nudge mood, attention, and cognitive flexibility without crossing into the full experience. The practitioner claim adds a second layer. Microdosing is said to loosen rigid mental habits just enough that the person can notice a new option: make the difficult phone call, begin the creative work, sit with the emotion, stop scrolling, choose the walk. This is why many practitioners combine it with journaling, meditation, therapy homework, or intention-setting. The dose is an opener, not the whole practice. The controlled evidence is much less confident than the culture around it. Observational studies find that microdosers report better mood, focus, creativity, and wellbeing. Placebo-controlled work complicates that story. The 2021 self-blinding citizen-science study led by Balazs Szigeti found that people improved across several measures, but those who unknowingly took placebo improved too; expectation and unblinding explained a large part of the reported benefit. Other controlled low-dose studies find small, mixed, or task-specific effects rather than the broad upgrade people often claim. The honest reading is not that "nothing happens." It is that microdosing is difficult to separate from expectation, selection bias, lifestyle changes, and careful self-observation. The practice may help some people, and some acute drug effects are measurable. The strong claims, daily creativity, depression relief, effortless focus, stable emotional healing, are not established by the evidence now available. ## Claimed benefits Microdosers most often claim mood lift, reduced anxiety, sharper focus, creative flow, more patience, and a sense that ordinary life is easier to meet. The practice attracts people who don't want the disruption of a full psychedelic session: workers, parents, artists, founders, therapists, meditators, and people who are curious about psychedelics but wary of losing control. The productivity culture around microdosing is one reason it spread so quickly. In that frame, the dose is a tool for better work: more flexible thinking, less procrastination, better problem-solving, less social friction. In the wellness frame, the same practice becomes mood support, spiritual sensitivity, or a way to soften into meditation and daily ritual. Those frames overlap, but they point the practice in different directions. One asks, "Did I perform better?" The other asks, "Did I relate differently to myself and the day?" The cautious conclusion is modest. Microdosing may create a useful ritual of attention around mood, behavior, and intention. It may produce small pharmacological effects for some people. It also carries a placebo component large enough that any serious practitioner has to treat expectation as part of the practice, not as an embarrassment to be hidden. ## Training and certification norms There is no recognized license to be a microdosing practitioner. The practice spreads through books, podcasts, online communities, retreat and coaching circles, and underground networks. Some coaches have clinical backgrounds or psychedelic-facilitation training; many don't. A certificate in microdosing is not medical training, psychotherapy training, or legal authority to advise on controlled substances. The most credible norm is informed self-tracking. Practitioners who take the practice seriously learn the difference between anecdote and evidence, keep records, avoid making medical claims from a few good days, and know when the question has moved beyond self-experiment into professional care. Microdosing sits close to medicine, therapy, spirituality, and drug culture at once. That crossing is exactly why it needs a sober frame. ## Related practices and systems Microdosing belongs among the self-directed wellness practices of [The Ways](ways.md), especially near [breathwork](breathwork.md), [meditation](meditation.md), and other methods people use to regulate state across ordinary life. It also belongs to the larger psychedelic cluster alongside ayahuasca, psychedelic-assisted therapy, and entheogens. Those last two are not yet article targets here, so they remain plain prose until the book has on-disk entries for them. Its sharpest contrast is [Ayahuasca](ayahuasca.md): a full ceremonial encounter with a strong brew, guide, songs, purging, and an interpretive container. Microdosing is smaller, more private, more repetitive, and more vulnerable to the self-optimization habits of wellness culture. The risk edge is [Psychedelic Harms](psychedelic-harms.md), where the medical, psychological, provider, legal, and product-quality questions belong. ## Sources - James Fadiman, *The Psychedelic Explorer's Guide* (Park Street Press, 2011) — the practitioner source that popularized the one-day-on, two-days-off microdosing schedule now often called the Fadiman protocol. - James Fadiman and Sophia Korb, ["Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration"](https://doi.org/10.1080/02791072.2019.1593561) (*Journal of Psychoactive Drugs*, 2019) — an early report from a large self-report sample, useful for the claims microdosers make and the limits of uncontrolled data. - Vince Polito and Richard J. Stevenson, ["A systematic study of microdosing psychedelics"](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211023) (*PLOS ONE*, 2019) — observational study reporting changes in mood, attention, and personality measures across a microdosing period without a placebo-controlled design. - Balazs Szigeti et al., ["Self-blinding citizen science to explore psychedelic microdosing"](https://elifesciences.org/articles/62878) (*eLife*, 2021) — placebo-controlled citizen-science study finding improvement in both microdose and placebo groups, with expectancy explaining much of the reported benefit. - A. K. Bershad et al., ["Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers"](https://doi.org/10.1038/s41386-020-00883-6) (*Neuropsychopharmacology*, 2020) — controlled low-dose LSD study used here for the claim that acute measurable effects exist but do not amount to broad validated benefit. --- - [Next: Homeopathy](homeopathy.md) - [Previous: Somatic & Wellness Modalities](somatic-wellness.md)